Analyzes of Cerebrospinal Fluid in Autoimmune Systemic Diseases

Göteborg University1 site in 1 country30 target enrollmentJune 2009

ConditionsSjogrens Syndrome

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Sjogrens Syndrome
Sponsor: Göteborg University
Enrollment: 30
Locations: 1
Primary Endpoint: Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Detailed Description

The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Registry

clinicaltrials.gov

Start Date

June 2009

End Date

April 2019

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Göteborg University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•fulfill the ACR-criteria for primary Sjogrens syndrome,
•age above 18 years old

Exclusion Criteria

•other CNS-disease

Outcomes

Primary Outcomes

Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome

Time Frame: June 2009 - June 2015